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Abstract
In the search for novel anticancer drugs, the potassium channel KV10.1 has emerged as an
interesting cancer target. Here, we report a new group of KV10.1 inhibitors, namely the pur-
purealidin analogs. These alkaloids are produced by the Verongida sponges and are known
for their wide variety of bioactivities. In this study, we describe the synthesis and characteri-
zation of 27 purpurealidin analogs. Structurally, bromine substituents at the central phenyl
ring and a methoxy group at the distal phenyl ring seem to enhance the activity on KV10.1.
The mechanism of action of the most potent analog 5 was investigated. A shift of the activa-
tion curve to more negative potentials and an apparent inactivation was observed. Since
KV10.1 inhibitors can be interesting anticancer drug lead compounds, the effect of 5 was
evaluated on cancerous and non-cancerous cell lines. Compound 5 showed to be cytotoxic
and appeared to induce apoptosis in all the evaluated cell lines.
Introduction
Although many efforts have been made to prevent and treat cancer, it is still one of the leading
causes of death worldwide, with 8.8 million cancer deaths in 2015 [1]. A targeted approach as
used in precision or personalized medicine could enhance the specificity of the treatment and
minimize the negative side effects. The voltage-gated potassium channel human ether à go-go
1 (hEag1, KV10.1) represents an interesting cancer target because of its ectopic expression in
over 70% of human cancers [2]. Moreover, transfection of rat Eag1 into mammalian cells
induced features that are characteristic for malignant cell transformation [3]. KV10.1 inhibitors
are considered to be lead compounds in the development of novel anticancer drugs [2]. In
order to identify novel KV10.1 inhibitors or modulators, the effect of synthetic bromotyramine
alkaloids on KV10.1-expressing oocytes was electrophysiologically investigated.
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Bromotyrosine alkaloids are a large group of marine sponge metabolites mainly from the
order Verongida, found at the coasts of Southeast Asia, Oceania, Japan and China [4–7].
Sponges have already shown to be a very fertile source of new toxins as they contain many sec-
ondary metabolites [8,9]. They have defensive, antibiotic, antiangiogenic, antiproliferative,
hemolytic and cytotoxic properties. They inhibit mitosis and the assembly of microtubuli and
they induce cytotoxic cell death [9]. In this way, metabolites that induce apoptosis might have
potential as anticancer drugs [10]. The most striking sponge-derived compounds are the
nucleosides spongothymidine and spongouridine, isolated from the Tectitethya crypta. They
were the first marine derived compounds that were developed into a pharmaceutical drug. A
derivative of these nucleosides is cytarabine (AraC), that is currently used as an anticancer
agent in the treatment of leukemia [9–11].
A novel bromotyrosine purpurealidin J 1 (Fig 1) was found among other bromotyrosines
(e.g. purpurealidin I 2, aplysamine 2 3) in sponge Pseudoceratina (Psammaplysilla) purpurea
by Tilvi and D’Souza [12]. These bromotyrosines acted as an inspiration for the syntheses of
simplified amide analogs using bromotyramine purpurealidin E 4 as an amine starting mate-
rial. As the nomenclature of the bromotyrosines is quite heterogeneous [6], we refer to our
synthetic compounds as purpurealidin analogs. The effect of several synthetic analogs of these
marine metabolites on KV10.1 was investigated. Several simplified purpurealidin analogs were
identified to be KV10.1 modulators. The purpurealidin analog 5 (Fig 1) was found to be the
most potent one and its effect on KV10.1-expressing oocytes and on various cancer and non-
cancerous mammalian cell lines was investigated.
Materials and methods
Large scale synthesis of analog 5
All reactions were carried out using commercially available starting materials unless otherwise
stated. The melting points were measured with Stuart SMP40 automated melting point appa-
ratus and are uncorrected. 1H NMR (300 MHz) and 13C NMR (75 MHz) spectra in CDCl3 or
d6-DMSO at ambient temperature were recorded on a Varian Mercury Plus 300 spectrometer.
Chemical shifts (δ) are given in parts per million (ppm) relative to the NMR reference solvent
signals (CDCl3: 7.26 ppm; d6-DMSO: 2.50 ppm). Multiplicities are indicated by s (singlet), br s
(broad singlet), d (doublet), dd (doublet of doublet), t (triplet), dt (doublet of triplets), q (quar-
tet) and m (multiplet). The coupling constants J are quoted in Hertz (Hz). LC-MS and HRMS-
Fig 1. Marine bromotyrosines 1–4 and the most potent KV10.1 modulator analog 5.
https://doi.org/10.1371/journal.pone.0188811.g001
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spectra were recorded using Waters Acquity UPLC1-system (with Acquity UPLC1 BEH
C18 column, 1.7 μm, 50 × 2.1 mm, Waters) with Waters Synapt G2 HDMS with the ESI (+),
high resolution mode. The mobile phase consisted of H2O (A) and acetonitrile (B) both con-
taining 0.1% HCOOH. Microwave syntheses were performed in sealed tubes using Biotage
Initiator+ instrument equipped with an external IR sensor. The flash chromatography was
performed with Biotage SP1 flash chromatography purification system with 254 nm UV-detec-
tor using SNAP KP-Sil 10, 25, 50 or 100 g cartridges. The TLC-plates were provided by Merck
(Silica gel 60-F254) and visualization of the amine compounds was done using ninhydrin
staining.
2-(3,5-Dibromo-4-hydroxyphenyl)ethan-1-amine hydrobromide (7)
Br2 (6.87 mL, 122 mmol, 2.5 equiv) was added dropwise (5 min) to a precooled solution of
tyramine 6 (8.50 g, 49.0 mmol) in MeOH (40 mL) and the resulting mixture was stirred at
60˚C for 14 h. The reaction mixture was then cooled to 0˚C, filtered and the pale yellow solid
residue was washed with Et2O (40 mL). The crude product was further dried under high vac-
uum to give 7 as a light yellow solid (15.3 g, 94%). 1H NMR (300 MHz, d6-DMSO) δ 9.77 (s,
1H), 7.77 (br s, 3H), 7.45 (s, 2H), 3.02 (t, J = 7.2 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H). 13C NMR
(75 MHz, d6-DMSO) δ 149.9, 133.0, 132.1, 112.5, 40.1, 31.7. HRMS (TOF-ESI+): calcd for
C8H10Br2NO [M+H]+: 293.9129, found: 293.9128.
tert-Butyl (3,5-dibromo-4-hydroxyphenethyl)carbamate (8) [13]
A solution of di-tert-butyl dicarbonate (15.5 g, 71.1 mmol, 1.4 equiv) and triethylamine (17.7
mL, 127 mmol, 2.5 equiv) in MeOH (40 mL) was added dropwise to a stirred solution of 7
(16.8 g, 50.8 mmol) in MeOH (100 mL) under argon over a period of 15 min. The reaction
mixture was then brought to rt, further stirred for 14 h and then concentrated in vacuo. EtOAc
(30 mL) was added, washed with a 2 M solution of HCl in H2O (3 × 20 mL) and a saturated
solution of NaHCO3 in water (3 × 20 mL). The organic layer was dried over anhydrous
Na2SO4, filtered and evaporated to dryness to give crude 8 as a white solid (18.6 g, 93%).
1H
NMR (300 MHz, CDCl3) δ 7.28 (s, 2H), 5.84 (s, 1H), 4.54 (br s, 1H), 3.31 (q, J = 6.7 Hz, 2H),
2.69 (t, J = 7.0 Hz, 2H), 1.44 (s, 9H).13C NMR (75 MHz, CDCl3) δ 155.9, 148.1, 133.8, 132.3,
110.0, 41.8, 34.9, 28.5. Note: one peak under CDCl3.
tert-Butyl [3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]
carbamate (9) [4]
A mixture of 8 (18.6 g, 47.1 mmol), 3-chloro-N,N-dimethylpropan-1-amine hydrochloride
(8.93 g, 56.5 mmol, 1.2 equiv), and K2CO3 (19.5 g, 141 mmol, 3.0 equiv) in acetone (150 mL)
was refluxed under argon atmosphere for 24 h. It was then concentrated in vacuo and a 1 M
solution of NaOH in H2O (100 mL) was added to the resulting residue, and the mixture was
stirred for 10 min and extracted with dichloromethane (DCM, 100 mL). The organic layer was
washed with a 1 M solution of NaOH in H2O (60 mL) and the combined aqueous phases were
back-extracted with DCM (100 mL). The combined organic layers were dried over anhydrous
Na2SO4 and concentrated to give a thick yellow liquid. This was then refluxed in n- hexane
(180 mL) and allowed to crystallize to produce 9 as a white solid (18.1 g, 80%). Mp. 84.6–85.6
˚C. 1H NMR (300 MHz, CDCl3) δ 7.31 (s, 2H), 4.58 (br s, 1H), 4.03 (t, J = 6.5 Hz, 2H), 3.31
(q, J = 6.8 Hz, 2H), 2.70 (t, J = 7.0 Hz, 2H), 2.59–2.37 (m, 2H), 2.26 (s, 6H), 2.09–1.92 (m, 2H),
1.43 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 155.9, 152.0, 137.7, 133.0, 118.4, 79.7, 72.1, 56.5,
45.7, 41.6, 35.2, 28.5, 28.5. HRMS (TOF-ESI+): calcd for C18H29Br2N2O3 [M+H]+: 479.0545,
found: 479.0546.
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Purpurealidin E (4) [4]
A mixture of 9 (18.1 g, 37.6 mmol) and trifluoroacetic acid (TFA, 14.4 mL, 188 mmol, 5.0
equiv) in DCM (10 mL) was stirred under argon atmosphere for 24 h at room temperature.
It was then concentrated by gentle air flow and the residual TFA was removed in vacuo. The
residue was dissolved to EtOAc (100 mL) and washed with a 2 M solution of NaOH in H2O
(2 × 50 mL). The aqueous phase was back-extracted with EtOAc (2 × 50 mL), the combined
organic layers were dried over anhydrous Na2SO4 and concentrated to give 4 as a pale yellow
liquid. 1H NMR spectrum showed some unreacted material, so the crude mixture was once
again treated with TFA (20 mL + 10 mL) and stirred for another 36 h. The reaction mixture
was then treated with a 10 M solution of NaOH in H2O (50 mL). H2O (25 mL) was added and
extracted using EtOAc (3 × 100 mL). The combined organic layers were dried over anhydrous
Na2SO4 and concentrated to give 4 as a pale yellow thick liquid (18 g, quant.). Rf 0.37 (DCM/
MeOH, 4:1). 1H NMR (300 MHz, CDCl3) δ 7.33 (s, 2H), 4.03 (t, J = 6.5 Hz, 2H), 2.93 (t, J = 6.8
Hz, 2H), 2.64 (t, J = 6.7 Hz, 2H), 2.59–2.50 (m, 2H), 2.27 (s, 6H), 2.11–1.96 (m, 2H), 1.31 (br s,
2H). 13C NMR (75 MHz, CDCl3) δ 151.8, 138.7, 133.0, 118.3, 72.1, 56.5, 45.7, 43.3, 38.9, 28.5.
HRMS (TOF-ESI+): calcd for C13H21Br2N2O [M+H]+: 379.0024, found: 379.0021.
3-Chloro-N-[3,5-dibromo-4-[3-(dimethylamino)propoxy]phenethyl]-
4-methoxybenzamide (5)
A 20-mL MW tube was charged with 3-chloro-4-methoxybenzoic acid (0.59 g, 3.2 mmol, 1.5
equiv), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCHCl, 0.76 g, 4.0
mmol, 1.5 equiv), and 1-hydroxybenzotriazole (HOBt, 0.53 g, 4.0 mmol, 1.5 equiv). The amine 4
(1.0 g, 0.26 mmol) was then added, followed by N,N-diisopropylethylamine (DIPEA, 0.69 mL, 4.0
mmol, 1.5 equiv). Dry DCM (15 mL) was added and the reaction mixture was irradiated with
MW at 60˚C for 2 h. The formation of the product was monitored with TLC (n-hexane with 1%
Et3N-acetone 1:1). The reaction mixture was then diluted with DCM (10 mL) and washed with a 2
M solution of NaOH in H2O (2 × 20 mL). The combined aqueous layers were back-extracted with
DCM (25 mL), dried over anhydrous Na2SO4 and evaporated to give the crude product (1.5 g).
The crude products of two batches were combined (approx. 3.0 g) and subjected to flash chroma-
tography (eluent: n-heptane, 1% Et3N: DCM, 1% Et3N, gradient 50–100%) to give 5 a white solid
(1.0 g, 34%). This was repeated and the yield was found to be 30–35%. The batches were combined
(6.12 g), subjected again to flash chromatography (eluent n-heptane, 2% Et3N: DCM, 2% Et3N,
gradient 20–100%). The crude compound 5 was then treated with DCM and n-heptane (1:5) to
make a flowing suspension of the product that was concentrated in vacuo. The resulting white
solid was washed with n-heptane (5 × 10 mL) to give 5 as a white solid (5.84 g, 33% yield). 1H
NMR (400 MHz, d6-DMSO) δ 8.49 (t, J = 5.5 Hz, 1H), 7.86 (d, J = 2 Hz, 1H), 7.79 (dd, J = 2.2, 8.7
Hz, 1H), 7.72 (s, 2H), 7.22 (d, J = 8.7 Hz, 1H), 3.94 (t, J = 6.5 Hz, 2H), 3.46 (t, 6.8 Hz, 2H), 2.80 (t,
J = 6.9 Hz, 2H), 2.51 (t, J = 7.1 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 166.1, 157.6, 152.0, 137.5,
132.9, 129.0, 127.4, 126.9, 122.7, 118.4, 111.5, 77.4, 77.0, 76.7, 72.0, 56.4, 56.3, 45.5, 41.0, 34.5, 28.3.
HRMS (ESI): calcd for C21H26N2O3ClBr2 [M+H]
+, 546.9999; found, 547.0002. More information
about the synthesis of the analogs can be found in the Supporting Information (S1 Appendix).
Expression of voltage-gated ion channels in Xenopus laevis oocytes
For the expression of hKV10.1a (GeneBank accession number: NM_002238.3) in Xenopus
oocytes, the hKV10.1a-pSGEM plasmid was linearized with SfiI (ThermoFisher Scientific, Wal-
tham, Massachusetts, USA) and transcribed using the T7 mMESSAGE-mMACHINE tran-
scription kit (Ambion1, Carlsbad, California, USA).
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Stage V-VI Xenopus laevis (African clawed frog) oocytes were isolated by partial ovariec-
tomy. Mature female animals were purchased from Nasco (Fort Atkinson, Wisconsin, USA)
and were housed in the Aquatic Facility (KU Leuven) in compliance with the regulations of
the European Union (EU) concerning the welfare of laboratory animals as declared in Direc-
tive 2010/63/EU. The use of Xenopus laeviswas approved by the Animal Ethics Committee of
the KU Leuven (Project nr. P038/2017). Prior to harvesting the oocytes, the animals were anes-
thetized by a 15-min submersion in 0.1% tricaine methanesulfonate (pH 7.0). Isolated oocytes
were defolliculated with 1.5 mg/mL collagenase.
Defolliculated oocytes were injected with 4 nL of cRNA at a concentration of 1 ng/nL using
a micro-injector (Drummond Scientific1, Broomall, Pennsylvania, USA). The oocytes were
incubated in a solution containing (in mM): NaCl, 96; KCl, 2; CaCl2, 1.8; MgCl2, 2 and
HEPES, 5 (pH 7.4), supplemented with 50 mg/L gentamycin sulfate.
Electrophysiological recordings
Two-electrode voltage-clamp recordings were performed at room temperature (18–22˚C)
using a Geneclamp 500 amplifier (Molecular Devices, USA) controlled by a pClamp data
acquisition system (Axon Instruments1, Union City, California, USA). Whole cell currents
from oocytes were recorded 1–4 days after injection. Bath solution composition was (in mM):
NaCl, 96; KCl, 2; CaCl2, 1.8; MgCl2, 2 and HEPES, 5 (pH 7.5). Voltage and current electrodes
were filled with a 3 M solution of KCl in H2O. Resistances of both electrodes were kept
between 0.5 and 1.5 MO. The elicited KV10.1 currents were filtered at 1 kHz and sampled at 2
kHz using a four-pole low-pass Bessel filter. Leak subtraction was performed using a -P/4 pro-
tocol. KV10.1 currents were evoked by 2-s depolarizing pulses to 0 mV from a holding poten-
tial of -90 mV unless otherwise indicated.
Live cell imaging
Cell cultures. Cell lines SH-SY5Y (ACC 209), DU145 (ACC 261), LNCaP (ACC 256) and
NIH-3T3 (ACC 59) were purchased from DSMZ (Germany). MDA-MB-435S (HTB 129) and
hTERT RPE-1 (CRL 4000) were obtained from ATCC (USA). Cell lines were cultured in their
recommended media Supplemented with 10% or 15% FCS (PAA laboratories, Germany) at
37˚C in humidified 5% CO2 atmosphere. Cell lines used in this study are given in Table 1. All
media were purchased from ThermoFisher Scientific (Waltham, Massachusetts, United
States).
Proliferation, cytotoxicity and apoptosis assays. Cell proliferation, cytotoxicity and apo-
ptosis were assessed in a 96-well microtiter plate by live-cell imaging using an IncuCyte Zoom
System (Essen BioScience, UK). Cell proliferation was monitored in terms of cell confluency
(%). Cell cytotoxicity was assessed by the CellTox Green Dye assay (Promega, Madison,
Table 1. Cell lines used for proliferation, cytotoxicity and apoptosis assays.
Cell line Description Medium
SH-SY5Y Human neuroblastoma cell line RPMI + 15% FCS
DU145 Human prostate cancer cell line DMEM + 10% FCS
LNCAP Human prostate cancer cell line RPMI + 15% FCS
NIH-3T3 Mouse embryonic fibroblast cell line DMEM + 10% FCS
MDA-MB-435S Human melanoma cell line RPMI + 10% FCS
hTERT RPE-1 Human epithelial cell line DMEM:F12 + 10% FCS
+ 10 μg/mL hygromycin B
https://doi.org/10.1371/journal.pone.0188811.t001
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Wisconsin, USA). The Incucyte Caspase-3/7 apoptosis assay (Essen BioScience, UK) was used
to evaluate the effect of compound 5 on the apoptotic pathway. As negative controls media
supplemented with 0.05% of DMSO were used.
Data analysis
All electrophysiological data are presented as means ± S.E.M of n 3 independent experiments
unless otherwise indicated. All data was analyzed using pClamp Clampfit 10.4 (Molecular
Devices1, Downingtown, Pennsylvania, USA) and OriginPro 8 (Originlab1, Northampton,
Massachusetts, USA) or GraphPad Prism 5 software (GraphPad Software, Inc., San Diego, Cali-
fornia, USA).
Live-cell imaging data were collected from the IncuCyte Zoom software and analyzed using
GraphPad Prism 5 software. Proliferation was measured as Phase Object Confluence (%), cyto-
toxicity and apoptosis were measured as Green Object Count (1/mm2). All data are repre-
sented as mean S.E.M of n = 6 different wells.
Results
Compound synthesis
Synthesis of the simplified purpurealidin analogs was based on the amide coupling of purpur-
ealidin E 4 or tyramine derivative 11 with aromatic carboxylic acids. Purpurealidin E 4 and 11
were synthesized in four steps from tyramine in an overall yield of 80% and 82%, respectively,
improving the literature yields (Fig 2) [4,13,14]. The synthetic route started with the bromina-
tion of tyramine. The dibrominated 7 was obtained in 97% yield followed by a straightforward
tert-butyloxycarbonyl (Boc) protection of the amino moiety. The third step of the route was
the alkylation of the phenolic hydroxyl using potassium carbonate as a base in acetone. The
last step was a quantitative removal of Boc-protecting group to give compounds 4 and 11. For
Fig 2. Synthesis of N,N-dimethyl amines (5, 12–31) and carbon analogs 32 and 33. The synthesis
scheme of the N-monomethyl amine analogs 43–46 is depicted in Fig 3. The structures of the final
compounds are presented in Fig 4.
https://doi.org/10.1371/journal.pone.0188811.g002
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the compounds 12–22, 25, 26, 32 and 33 the amide coupling was carried out at room tempera-
ture using EDC-mediated coupling with the corresponding carboxylic acid in the presence of
HOBt and DIPEA in DCM. The use of microwave irradiation at 60˚C reduced the reaction
time to 2 hours for compounds 5, 23, 24, and 27–31. A large scale synthesis of our hit com-
pound 5 was achieved following the same synthetic sequence that was used for a small scale
synthesis. This resulted in 5.8 g of the compound 5 in 23% overall yield.
Compound 34 with a free phenolic hydroxy group was synthesized to study the importance
of the N,N-dimethylpropylamino chain for the activity. The alkylation led to the non-brominated
analog 35. This approach provides a short synthesis route and enables the variation of the amine
moiety. Synthesis route for 35 is presented in the Supporting Information (S1 Appendix).
N-monomethyl derivatives 43–46 were synthesized from the compound 8 using acid-stable
trifluoroacetamide protecting group (Fig 3). Initially, the treatment of 3-chloromethyl amine
hydrochloride with trifluoroacetic anhydride (TFAA) in the presence of triethylamine gave 36
in 82% yield. The subsequent O-alkylation of 8 with 36 in the presence of Cs2CO3 in N,N-
dimethylformamide gave 37 in 70% yield. When 37 was treated with trifluoroacetic acid
(TFA), the Boc group was selectively and quantitatively removed, whereas the trifluoroacetyl
group remained intact. The resulting amine 38 was coupled with various aromatic carboxylic
acids using EDC-mediated amide coupling under microwave conditions with 56–71% yields.
Finally, removal of the trifluoroacetyl group using K2CO3 in MeOH gave N-monomethyl pur-
purealidin I analogs 43–46 (Fig 3).
Fig 3. Synthesis of N-monomethyl amine analogs 43–46. The structures of the final compounds are
presented in Fig 4.
https://doi.org/10.1371/journal.pone.0188811.g003
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Synthetic purpurealidin analogs are able to inhibit KV10.1
Since secondary metabolites of marine sponges are known to possess a wide array of interest-
ing bioactivities, their effect on the cancer-related potassium channel KV10.1 was evaluated. A
preliminary screening showed that bromotyramine alkaloids were able to inhibit KV10.1 chan-
nels. In order to investigate the structure-activity relationship, 27 simplified bromotyramine
analogs with the β-(hydroxyimino) amide parts replaced with amide moieties were synthesized
and their effect on KV10.1 was electrophysiologically evaluated. In Fig 4 an overview of these
27 synthetic bromotyramine analogs, also known as the purpurealidin analogs is given. Their
inhibitory effect on KV10.1 was evaluated by perfusion of 40 μM of each compound as an
extracellular solution. The average current inhibition (%) is shown in Fig 5.
Compound 5 inhibits KV10.1 in a dose- and voltage-dependent manner
To investigate the mechanism of action, the most potent purpurealidin derivative of this study,
compound 5, was selected. At 40 μM, compound 5 inhibits the KV10.1 current by 86.9 ± 1.3%
(Fig 5). In Fig 6A, representative traces are shown in control situation (black line) and during
perfusion of 10 μM (dark grey line) and 60 μM (light grey line) of 5. At a concentration of
10 μM, compound 5 inhibits KV10.1 by 51 ± 3%, this inhibition is reversible as shown in Fig
6C. The concentration-dependency of the inhibition was further evaluated using 8 increasing
concentrations ranging from 0.04 μM to 80 μM. To calculate the IC50 value, the curve was fit-
ted with the logistic dose-response equation, y =
A1   A2
1þðIC50=½toxinÞ
nH + A2 where y represents the per-
centage of current inhibition, A1 the initial inhibition at the lowest toxin concentration (0%),
A2 the final inhibition at the highest toxin concentration, IC50 the half maximal inhibitory
toxin concentration and nH the Hill coefficient. The calculated IC50-value and Hill coefficient
are respectively 7.7 ± 1.0 μM and 1.6 ± 0.3 μM (Fig 6B). A more in-depth electrophysiological
characterization was conducted with compound 5 at 10 μM, a concentration close to the IC50-
value. In Fig 6C, a representative normalized time-dependent profile of the KV10.1 current
during wash-in and wash-out of purpurealidin analog 5 is shown for one experiment. One
sweep after perfusion with compound 5, the expected inhibition of ± 50% is already reached.
In Fig 6D the wash-in and wash -out time is estimated. Using a one phase decay equation y =
((y0 – a)e
-t/τ + a) with y0 = 0.9795 and a = 0.43, the exponential time constant (τ) was deter-
mined as 5.3 s. The wash-out of 5 is slower than the wash-in (τ ~ 20s). This time constant was
determined using a one phase association equation [y = y0 + (a – y0)(1 – e
-t/τ)] with y0 = 0.4327
and a = 0.9858.
To investigate the effect of compound 5 on the activation of KV10.1, 1-s activating steps
from the holding potential -90 mV to 65 mV with 5 mV increments were applied. In Fig 7A
(left) the representative traces are shown during perfusion of ND96 (control) and 10 μM of
compound 5. It appears that for pulse potentials 40 mV, the steady-state current amplitude
reaches a plateau value in the presence of compound 5. In the right panel, the experiments of
the left panel were repeated with an external high potassium solution HK ([K+]e = 96 mM).
Here, this effect was less pronounced at the tested pulse potentials.
In Fig 7B, the normalized current amplitude (I/Imax,control) in control condition (closed cir-
cles) and during 5 perfusion (open circles) is plotted against the pulse potential. The current-
voltage curve reaches a plateau during 5 perfusion. This can indicate that apart from the mod-
ulation of the channel activation, compound 5 modulates KV10.1 in an additional manner.
In Fig 7C, the normalized current amplitude (I/Imax) was plotted against the corresponding
pulse potentials and fitted with the Boltzmann equation, y =
A1   A2
1þe
ðV  V1=2Þ=k
+ A2, where y repre-
sents the normalized current (I/Imax), A1 is the initial y-value and A2 is the final y-value, Imax is
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the maximal current, V is the test voltage, V1/2 is the half-maximal voltage and k is the slope
factor. A clear shift (ΔV1/2 = 21.0 ± 1.6 mV), from control condition (V1/2 = 23.2 ± 0.4 mV) to
more negative potentials (V1/2 = 2.1 ± 0.4 mV) was observed. The slope factor (kComp5 =
13.8 ± 0.3) was not significantly altered from control condition (kcontrol = 15.5 ± 0.4). A less
pronounced shift was observed in HK solution (ΔV1/2 = 14.8 ± 2.1 mV), from control condi-
tion (V1/2 = 39.3 ± 1.7 mV) to more negative potentials (V1/2 = 24.5 ± 1.3 mV). The slope factor
(kComp5 = 14.5± 1.0) was not significantly altered from control condition (kcontrol = 15.7 ± 0.9).
Fig 4. Structures of final amide compounds 5, 12–33, 35 and 43–46. Compound 34 is not shown in this
overview, since it is considered as a precursor and not a final compound (see S1 Appendix).
https://doi.org/10.1371/journal.pone.0188811.g004
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When the current inhibition (%) is plotted against the applied pulse potential (Fig 7D), a
clear voltage-dependent effect is observed. When the pulse potential increases, the current
inhibition increases. This increase appears to be biphasic, an important increase until -5 mV
(ND96) or 10 mV (HK) and a less pronounced increase at more depolarized potentials. At
lower depolarizing potentials near the activating threshold, very little current inhibition is
observed. However, when more channels open, the inhibitory effect initially increases fast.
To investigate if compound 5 binds specifically to open or closed KV10.1 channels, several
electrophysiological protocols were used. In an initial experiment, KV10.1-expressing oocytes
were perfused with 10 μM of compound 5. The membrane potential of the oocytes was
clamped at -90 mV prior to the addition of 5. After 10 minutes, a 2-second depolarizing pulse
to 0 mV was applied (Fig 8A). A 53 ± 4% current inhibition was observed, which corresponds
indeed to the average current inhibition of KV10.1 by 10 μM of compound 5. These data could
suggest that purpurealidin analog 5 is able to bind to closed channels and is able to exert its
effect through this binding. However, as was shown in Fig 6C and 6D, the inhibitory effect is
very rapid which can skew this state-dependent observation. Therefore, an additional experi-
ment was conducted, a 20-second depolarizing continuous step to 30 mV without P/4 leak
subtraction was applied. During this step (around 5 s after the start of the activating step), the
perfusion of ND96 was changed to 10 μM of compound 5. After the addition of compound 5,
the current decreases (τ ~ 1.4 s) to approximately 50% of the control current (Fig 8B). This
observation indicates that compound 5 is able to inhibit the potassium current through bind-
ing to open Kv10.1 channels.
Compound 5 induces an apparent inactivation of KV10.1 channels
This shift of the activation curve to more negative potentials, is reminiscent of the KV10.1 acti-
vation curve shift observed in the presence of mibefradil [15]. This Ca2+ channel antagonist
Fig 5. Overview of the KV10.1 current inhibition for each compound (40 μM). Compound numbers are
assigned to the different analogs as shown in Fig 4. For each compound the KV10.1 current inhibition is given
as average ± SEM.
https://doi.org/10.1371/journal.pone.0188811.g005
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was recently described as a gating modifier of KV10.1 by Go´mez-Lagunas et al. Mibefradil
induces an apparent inactivation from open (O) state and early closed states (C1). In order to
evaluate if the shift of the activation curve to the left can be correlated with an induced inacti-
vation, a two-pulse protocol was used as described in [15]. This protocol consists of a variable
1.5-s prepulse step, ranging from -140 mV to 50 mV in 10-mV steps, followed by a 0.5-s test
pulse to 30 mV. In Fig 9 representative traces are shown in control condition (Fig 9A) and dur-
ing compound 5 perfusion (Fig 9B). In control condition, the characteristic acceleration of
activation with increasing prepulse potential was observed, but no apparent inactivation was
detected. This is consistent with the literature since KV10.1 is presumed to be a non-inactivat-
ing or very slowly inactivating channel. However, during addition of 5, an apparent inactiva-
tion is induced. Fig 9C shows the non-inactivating channel fraction (I2/I2,max) plotted against
the corresponding prepulse potential. I2 is the peak current measured during the test pulse,
I2,max is the maximal peak current elicited during the consecutive test pulses. The non-inacti-
vating channel fraction reaches a maximum around -50 mV, near the activation threshold of
the KV10.1 channels. This means that when the channels start to open, the inactivated channel
fraction reaches a minimum. This indicates that compound 5 induces an apparent open-state
inactivation upon prolonged depolarizations and also affects the gating of the channel at
hyperpolarized potentials.
Fig 6. Compound 5 inhibits KV10.1 in a concentration-dependent and reversible manner. (A) A
standard 2-s pulse protocol to 0 mV from the HP-90 mV was used. The KV10.1 current during ND96 (black),
10 μM 5 (dark grey) and 60 μM 5 (light grey) perfusion is shown. (B) Concentration-dependency of the
induced KV10.1 inhibition by compound 5 is fitted with a logistic dose-response equation. (C) Normalized
KV10.1 currents during wash-in and wash-out of compound 5 over time for one individual oocyte. (D)
Averaged normalized KV10.1 currents during wash-in and wash-out of compound 5 over time. The time
constants (τ) for wash-in and wash-out were respectively calculated with a one phase decay and an
association equation.
https://doi.org/10.1371/journal.pone.0188811.g006
Purpurealidin analogs and their effect on KV10.1
PLOS ONE | https://doi.org/10.1371/journal.pone.0188811 December 8, 2017 11 / 18
Competition experiment with mibefradil
Since the effect of compound 5 on KV10.1 is comparable to that of mibefradil (see discussion)
[15], a competition experiment with both inhibitors was performed. This experiment was
based on the competition plot of Chevillard and colleagues [16] and conducted as described by
Fig 7. Evaluation of the voltage-dependency of the KV10.1 inhibition by compound 5. In the left panel,
results obtained in a low extracellular potassium concentration (2 mM) are shown. In the right panel the same
experiments were replicated in a high extracellular potassium concentration (96 mM). (A) Representative
traces obtained in control condition and during perfusion of 10 μM 5 using an activation protocol as described
in the text. (B) The normalized current (I/Imax,control) in control condition (●) and during perfusion of 10 μM 5 (◯)
are plotted against the pulse potential (mV). The curves are fitted with the Boltzmann equation. (C) The
normalized current (I/Imax) in control condition (●) and during perfusion of 10 μM 5 (◯) are plotted against the
pulse potential (mV). The curves are fitted with the Boltzmann equation. (D) The current inhibition (%) at each
pulse potential, calculated as (1-I5/Ictrl) × 100%, was plotted against its corresponding potential (mV).
https://doi.org/10.1371/journal.pone.0188811.g007
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Go´mez-Lagunas and colleagues [15]. This competition plot gives an indication whether two
ligands compete for the same binding site on the target. First, the concentration of mibefradil
that inhibits KV10.1 to the same extent as 10 μM of compound 5 (52 ± 3%) was determined.
During 2-s depolarizing pulses to 0 mV, 10 μM of mibefradil inhibits KV10.1 by 50 ± 5%.
These start concentrations will for now on be referred to as 5o and Mbo. Subsequently, the
effect of several mixtures with different ratios/proportions (p) of compound 5 and mibefradil
on KV10.1 was investigated. The solutions contained a mixture of p
5o and (1-p)
Mbo with
p ranging from 0.0 to 1.0. For example; p = 0.0 means that the solution contains 0 μM 5 and
10 μM Mb, p = 0.2 indicates a solution of 2 μM 5 and 8 μM Mb etc. Representative traces for
p = 0.0, p = 0.5 and p = 1.0 are shown in Fig 10A. The inhibitory effect of 7 different ratios was
evaluated and the current inhibition (%) was plotted against the corresponding proportion (p)
(Fig 10B). All data points appear to form a horizontal line, a two-tailed Student’s t-test was per-
formed for each ratio against p = 1.0 (10 μM). This showed that there was no significant differ-
ence (NS). Since no clear maximum or minimum was reached, the competition plot indicates
that the inhibitors compete for the same binding site.
Fig 8. Evaluation of the state-dependency of the KV10.1 inhibition by compound 5. (A) During ND96
perfusion, a 2-s depolarizing pulse to 0 mV from the HP (-90 mV) was applied. The oocyte was then clamped
at the HP and the extracellular solution was changed to 10 μM 5. After 10 minutes, a 2-s depolarizing pulse to
0 mV was applied. (B) A 20-s depolarizing continuous step to 30 mV without P/4 leak subtraction was applied.
During this step, the perfusion of ND96 was changed to a 10 μM of compound 5 (arrow).
https://doi.org/10.1371/journal.pone.0188811.g008
Fig 9. Voltage-dependence of KV10.1 inactivation induced by compound 5. (A) Representative trace of
KV10.1 in control conditions during a two-pulse inactivation protocol. (B) Representative trace of KV10.1
during perfusion of 10 μM of compound 5 during a two-pulse inactivation protocol. (C) The non-inactivating
channel fraction (I2/I2,max) in control situation (◯) and during perfusion of 10 μM of compound 5 (●) was plotted
against the corresponding prepulse potential (mV).
https://doi.org/10.1371/journal.pone.0188811.g009
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Compound 5 shows a cytotoxic and proapoptotic effect on a variety of
cancerous and non-cancerous cell lines
To investigate if the KV10.1 modulator 5 is able to reduce the proliferation of KV10.1-over-
expressing cell lines, the effect of different concentration of 5 was evaluated on a variety of
mammalian cell lines. These cell lines included KV10.1-expressing cells such as the human
neuroblastoma cell line SH-SY5Y, the human prostate cancer cell line DUI45, the human mel-
anoma cell line MDA-MB-435S and the human epithelial cell line hTERT RPE-1. The effect of
5 was also investigated on two cell lines that are described to express an undetectable amount
of KV10.1 channels, namely the human prostate cancer cell line LNCaP and the mouse embry-
onic fibroblast cell line NIH-3T3 (Table 2).
The following concentrations of compound 5 were added to the different cell lines, 100 μM,
50 μM, 20 μM, 10 μM, 5 μM and 2 μM to assess its effect on cell proliferation (S1 Fig) and cyto-
toxicity (S2 Fig). Indicative IC50-values for the proliferation assays were obtained by plotting
the areas under the curve (AUC × 103) against the tested compound 5 concentrations and by
Fig 10. Competition plot with compound 5 and mibefradil. (A) Representative traces are shown in control
condition and during perfusion of 10 μM mibefradil (p = 0.0), a mixture of 5 μM mibefradil and 5 μM of
compound 5 (p = 0.5) and 10 μM of compound 5 (p = 1.0). (B) The current inhibition (%) observed after
perfusion of the 7 different mixtures is plotted against p, which represents the fraction of compound 5 in the
mixture.
https://doi.org/10.1371/journal.pone.0188811.g010
Table 2. Cell lines used for proliferation, cytotoxicity and apoptosis assays.
Cell line Description KV10.1 expression level Ref.
SH-SY5Y Human neuroblastoma cell line High [17]
DU145 Human prostate cancer cell line Intermediate [17]
LNCaP Human prostate cancer cell line Undetectable [17]
NIH-3T3 Mouse embryonic fibroblast cell line Undetectable [3]
MDA-MB-435S Human melanoma cell line Moderate [17]
hTERT RPE-1 Human epithelial cell line Moderate [17]
https://doi.org/10.1371/journal.pone.0188811.t002
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fitting the curve with a logistic dose-response equation. The EC50-values for the cytotoxicity
assays were calculated correspondingly (S3 Fig). These calculated values are shown in Table 3.
Although more data points would be necessary to calculate precise IC50 and EC50-values, it is
clear that compound 5 inhibits the proliferation and induces cytotoxicity in all the tested cell
lines in the low to middle micromolar range.
A dose-dependent antiproliferative and cytotoxic effect was not only observed on the
KV10.1-expressing cells but also on the control cell lines. It should be noted that a 48-h incuba-
tion of Xenopus oocytes with 10 μM concentration of compound 5 did not result in noticeable
deterioration of the oocyte quality (visual and electrophysiological observation).
To evaluate the effect of compound 5 on the apoptotic pathway, 100 μM, 50 μM and 20 μM
of 5 was added to the cell lines. After addition of the compound, caspase-3/7 activity was
detected in all the cell lines, indicating an induction of the apoptotic pathway (S4 Fig).
Discussion
Here we reported the identification of a novel group of KV10.1 inhibitors, namely the deri-
vatives of the bromotyramine purpurealidin E from the marine sponge Pseudoceratina pur-
purea. In this study, mainly the carboxyl part of the tyramine amide was studied. Based on the
KV10.1 inhibition results in Fig 5, the most active compound was 3-chloro-4-methoxyphenyl
derivative 5, and this substitution pattern also was confirmed in the case of 3-bromo-, 3-iodo-
and 3-methyl-4-methoxyphenyl derivatives 25, 29, and 30, respectively. These monohaloge-
nated analogs were more active than dihalogenated 4-methoxy derivatives (23, 26, 28) or 3,4-
dimethoxyphenol derivative 31. Also 4-methoxyphenyl derivative 21 had moderate activity, so
para-methoxy substitution seems to be important for KV10.1 inhibition. At the early stage of
the study, 3,5-dichlorophenyl derivative showed promising inhibition and therefore it was
used as a scaffold for structural modifications at the other end of the molecule. Replacement of
N,N-dimethylamino moiety at the end of the propylamino chain by isopropyl (compounds 32
and 33) caused a total loss of the activity and monomethylamine derivatives 43–46 were less
active. Similarly, the lack of bromine atoms in the tyramine ring in compound 35 abolished
the activity. Interestingly, no biological activity of purpurealidin E 4 has been previously re-
ported to the best of our knowledge. Screening of secondary marine metabolites on a panel of
ion channels could broaden are knowledge about the mode of action of these compounds and
could result in the identification of novel ion channels ligands.
The most potent derivative, compound 5 exerts a concentration- and voltage-dependent
inhibitory effect on Kv10.1 at low micromolar concentration. We suggest that compound 5 is
a gating modifier that binds to the voltage sensor of KV10.1 near the binding site of mibefradil.
Mibefradil is a Ca2+ channel antagonist and a KV10.1 gating modifier [15]. Like compound 5,
mibefradil shifts the activation curve to the left. Mibefradil seems to decrease the rate limiting
step of KV10.1 activation and thereby facilitates the activation. Mibefradil also induces an
Table 3. Antiproliferative and cytotoxic effect of compound 5 on different cell lines.
Cell line Antiproliferative effect (IC50) Cytotoxic effect (EC50)
SH-SY5Y 12.22 μM 15.29 μM
DU145 28.87 μM 60.41 μM
LNCAP 26.42 μM 40.37 μM
NIH-3T3 7.13 μM 4.58 μM
MDA-MB-435S 28.06 μM 16.48 μM
hTERT RPE-1 12.48 μM 15.60 μM
https://doi.org/10.1371/journal.pone.0188811.t003
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apparent open-state inactivation upon prolonged depolarization (Vm -50 mV) and hyperpo-
larization (Vm -70 mV). At hyperpolarized potentials, channels dwell in early closed states
(C1). It appears that at these potentials mibefradil induces a steady-state inactivation and stabi-
lizes this inactivated state. At more depolarized potentials, when the channels are in an open
state (O), mibefradil seems to induce an apparent open-state inactivation [15]. A similar effect
is observed for compound 5. Go´mez-Lagunas et al. suggest that mibefradil binds to the S1-S4
voltage sensor module and alters the channel gating. Our competition plot data (Fig 10) indi-
cates that the binding site of compound 5 on KV10.1 overlaps with the binding site of mibefra-
dil. However, this hypothesis needs to be confirmed by site-directed mutagenesis studies. Both
compounds are hydrophobic and carry one positive charge at pH 7.4 (S5 Fig). This suggests
that they are both able to bind to hydrophobic and negatively charged residues of KV10.1.
Compound 5 shows a clear dose-dependent cytotoxic and proapoptotic effect on Kv10.1
expressing- and non-expressing cell lines. These observed effects can therefore not only be
attributed to the effect of compound 5 on Kv10.1. Moreover, Kv10.1 is mostly described to be
involved in cell proliferation [18,19] and migration [20]. An effect on apoptosis is not yet
described. It is therefore presumed that the cytotoxic/proapoptotic effect of compound 5 is not
or only in part due to its effect on KV10.1. To unravel the exact mode of action of this com-
pound, more research is necessary.
Several sponge secondary metabolites, especially bromotyrosine derivatives, are known to
induce cytotoxicity and/or apoptosis in mammalian cells [6]. For example, it has been pro-
posed that the cytotoxic activity of psammaplin A, a natural bromotyrosine derivative from a
marine sponge is due to the inhibition of several important enzymes (histone deacetylase,
DNA methyltransferase etc.) by zinc chelation [21]. Psammaplin A also activates the peroxi-
some proliferator-activated receptor γ (PPARγ) and induces apoptosis in human breast cancer
cells [22]. Zhang et al. suggested previously that KV10.1 is involved in the regulation of PPARγ
expression [23].
Conclusion
In this research paper, we investigated if simplified synthetic analogs of purpurealidins are able
to inhibit the oncogenic potassium channel KV10.1 and if they exert antineoplastic effect on
cancer cell lines. The purpurealidin E analog 5 shifts the KV10.1 activation curve to the left and
induces an apparent inactivation. Since these effects are similar to those induced by the gating
modifier mibefradil, a competition experiment was conducted. Our data suggests that analog 5
is a KV10.1 gating modifier that binds to voltage sensor domain of KV10.1 on the same binding
site of mibefradil. Although compound 5 shows a cytototoxic effect on all the evaluated mam-
malian cell lines, it is still a valuable tool to study the gating of the cancer-related potassium
channel KV10.1. Our study also shows that marine secondary metabolites are interesting com-
pounds to consider in the search for novel ion channel ligands. These ligands cannot only be
used as pharmacological tools to investigate disease-related ion channels but can also be used
as templates for the design and synthesis of more potent and selective treatments for various
channelopathies such as cancer, epilepsy, and diabetes.
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